Get the Stockscreener App
1.90
1.60%
0.03
Climb Bio Inc stock is traded at $1.90, with a volume of 21,650.
It is up +1.60% in the last 24 hours and down -15.56% over the past month.
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
See More
Previous Close:
$1.87
Open:
$1.89
24h Volume:
21,650
Relative Volume:
0.06
Market Cap:
$127.20M
Revenue:
-
Net Income/Loss:
$-64.20M
P/E Ratio:
-0.8837
EPS:
-2.15
Net Cash Flow:
$57,000
1W Performance:
-1.55%
1M Performance:
-15.56%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.87
$1.945
1-Week Range:
$1.84
$2.05
52-Week Range:
$1.73
$5.47
Climb Bio Inc Stock (CLYM) Company Profile
Name
Climb Bio Inc
Sector
Industry
Phone
1-866-857-2596
Address
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
1.90 | 127.20M | 0 | -64.20M | 57,000 | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.43 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
706.50 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
666.13 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.51 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.77 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
Climb Bio Inc Stock (CLYM) Latest News
ForexTV | Small Business Resources - ForexTV.com
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Exclusive: Climb Bio Takes Center Stage at Major Healthcare ConferenceKey Details Inside - StockTitan
Bioethanol Market Anticipated to Climb to USD 130.46 Billion by 2030 - Industry Today
Novartis sets ‘ambitious’ target; Skyrizi, Rinvoq sales climb - BioPharma Dive
Sizzling Growth in Cell Culture Plates Market: Steady Climb from - openPR
Novo shares climb on early data for dual-acting obesity drug - BioPharma Dive
Coal miners climb after Trump offers praise at Davos (NYSE:BTU) - Seeking Alpha
Sensus leads med-tech stock rebound in 2024, year closes with modest sector gain - BioWorld Online
Climb Bio (NASDAQ:CLYM) Trading Down 0.5%Time to Sell? - MarketBeat
Climb Bio (NASDAQ:CLYM) Trading Down 0.5% – Should You Sell? - Defense World
Climb Bio enters licensing deal with Mabworks for CLYM116 development - MSN
Nanosensor Market Anticipated to Climb to USD 1302.22 Billion by 2030 - openPR
Personal Care Ingredients Market Anticipated to Climb to USD 22.48 Billion by 2030 - openPR
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Amanda Gorman | Biography, Poems, Books, Inauguration, & The Hill We Climb - Britannica
Insiders Could Have Profited By Holding onto Climb Bio Shares Despite 13% Drop - Simply Wall St
Fed Up With Waiting, Manhattan's Wealthy Return To The Luxury Market – 'New Normal' Of High Rates Accepted As Sales Climb 3.7% - Yahoo Finance
Inflation report could rattle markets after bond yields climb - Yahoo Finance
The week in pharma: action, reaction and insight – week to January 10 - The Pharma Letter
Methode Electronics, Inc (MEI) Has A Gold Mine On Its Hands - Stocks Register
Analysts Update Their Estimates For Brunswick Corp - Stocks Register
Xenia Hotels & Resorts Inc (XHR): Major Improvements, Worth A Look - Stocks Register
Qifu Technology Inc. ADR (QFIN) Recovers 163.24% From Low: Are We There Yet? - Stocks Register
Universal Health Services, Inc (UHS) Analyst Thoughts: How High Can It Go? - Stocks Register
Analysts Update Their Estimates For EPR Properties - Stocks Register
At $18.67 Price, Osisko Gold Royalties Ltd (OR) Is Sitting And Waiting - Stocks Register
Analysts Provide An Important Insights On Kodiak Gas Services Inc (KGS) - Stocks Register
Bank of Montreal (BMO): Worth A Small Bite At $97.44 - Stocks Register
Items Tagged with 'MIL-116' - BioWorld Online
Items Tagged with 'CLYM-116' - BioWorld Online
Items Tagged with 'Beijing Mabworks Biotech Co. Ltd.' - BioWorld Online
Items Tagged with 'Climb Bio Inc.' - BioWorld Online
Climb Bio licenses anti-APRIL monoclonal antibody from Mabworks - BioWorld Online
Deal Watch: Lilly Looks To Alchemab’s ‘Resilient’ Antibodies To Take On ALS - News & Insights
Mortgage rates climb for 4th straight week — to the highest level in 6 months - Yahoo Finance
UK Power Prices Climb as Light Winds to Tighten Market on Friday - Yahoo Finance
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy - The Manila Times
Aduro Clean Technologies to Host Virtual Fireside Chat on Thursday, January 23rd, 2025 - The Manila Times
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an - The Bakersfield Californian
Climb Bio Expands Pipeline Through an Exclusive License to - GlobeNewswire
Sana Biotechnology price target lowered to $7 from $8 at BofA - Yahoo Finance
Samsung’s Shares Climb After Nvidia Talk Offsets Profit Miss | Company Business News - Mint
NXP Semiconductors to Acquire TTTech Auto in $625 Million Deal, Shares Climb - Yahoo Finance
Ibio licenses long-acting anti-myostatin antibody from Astralbio - BioWorld Online
Climb Global Solutions (CLMB) Rose on Solid Results - Yahoo Finance
Amplitude, Asana see bullish views at Piper Sandler, stocks climb (NASDAQ:AMPL) - Seeking Alpha
Nvidia partner Hon Hai’s shares climb after AI spurs sales beat - Yahoo Finance
Investors Don't See Light At End Of bluebird bio, Inc.'s (NASDAQ:BLUE) Tunnel And Push Stock Down 38% - Simply Wall St
Infrastructure Products Distributor MRC Global Plans Stock Buyback; Shares Climb - Yahoo Finance
Bitcoin Mining Stocks Climb Pre-Market As Wall Street Eyes Robust Growth In 2025: Retail’s Divided - MSN
Climb Bio Inc Stock (CLYM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.43%
3.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):